Journal of Clinical Investigation · 2013 · 216 citations · 55 references
MedicineCell BiologyOncologyCell SignalingMolecular OncologySignal TransductionCancer Cell SignalingCancer GlycobiologyCancer MetabolismOncogene ActivationOncogenic Signaling PathwaysSignal Transduction In CancerAerobic GlycolysisCancer Signaling PathwaysGlycolysisGlycolytic PathwaysHexosamine Biosynthesis PathwayHexosamine Biosynthetic PathwayOncogenic TransformationTumor Metabolism
There is a considerable resurgence of interest in the role of aerobic glycolysis in cancer; however, increased glycolysis is frequently viewed as a consequence of oncogenic events that drive malignant cell growth and survival. Here we provide evidence that increased glycolytic activation itself can be an oncogenic event in a physiologically relevant 3D culture model. Overexpression of glucose transporter type 3 (GLUT3) in nonmalignant human breast cells activated known oncogenic signaling pathways, including EGFR, β1 integrin, MEK, and AKT, leading to loss of tissue polarity and increased growth. Conversely, reduction of glucose uptake in malignant cells promoted the formation of organized and growth-arrested structures with basal polarity, and suppressed oncogenic pathways. Unexpectedly and importantly, we found that unlike reported literature, in 3D the differences between "normal" and malignant phenotypes could not be explained by HIF-1α/2α, AMPK, or mTOR pathways. Loss of epithelial integrity involved activation of RAP1 via exchange protein directly activated by cAMP (EPAC), involving also O-linked N-acetylglucosamine modification downstream of the hexosamine biosynthetic pathway. The former, in turn, was mediated by pyruvate kinase M2 (PKM2) interaction with soluble adenylyl cyclase. Our findings show that increased glucose uptake activates known oncogenic pathways to induce malignant phenotype, and provide possible targets for diagnosis and therapeutics.
55
Otto Warbürg · Science · 1956 · 13.3K citations
A Gene-Expression Signature as a Predictor of Survival in Breast Cancer
Marc J. van de Vijver, Yudong D. He, Laura van ‘t Veer et al. · New England Journal of Medicine · 2002 · 6.5K citations · Full text
Medicine, Bioinformatics, Oncology +17
Prolonged Rapamycin Treatment Inhibits mTORC2 Assembly and Akt/PKB
Dos D. Sarbassov, Siraj M. Ali, Shomit Sengupta et al. · Molecular Cell · 2006 · 2.6K citations · Full text
Edward L. Giovannucci, David M. Harlan, Michael C. Archer et al. · Diabetes Care · 2010 · 2.2K citations · Full text
Medicine, Cancer Biology, Oncology +14